Levosimendan vs. Dobutamine in Patients with Septic Shock: A Systematic Review and Meta-Analysis with Trial...

Area of Science:

• Critical Care Medicine
• Cardiology
• Pharmacology

Background:

• Septic-induced cardiomyopathy (SICM) is a severe complication of septic shock, characterized by persistent hypoperfusion.
• Current management of SICM involves inotropes, but the comparative efficacy of different agents is not well-established.
• Optimizing inotropic therapy is crucial for improving outcomes in patients with septic shock and cardiac dysfunction.

Purpose of the Study:

• To compare the effectiveness of levosimendan versus dobutamine in patients with septic shock and persistent hypoperfusion.
• To evaluate the impact of levosimendan on mortality, length of stay, and key biomarkers in SICM.
• To determine the optimal inotropic agent for managing septic-induced cardiomyopathy.

Main Methods:

• A systematic review and meta-analysis of randomized clinical trials (RCTs) comparing levosimendan and dobutamine.
• Inclusion criteria focused on patients with septic shock and persistent hypoperfusion.
• Statistical analysis included random-effects modeling for summary estimates and Trial Sequential Analysis (TSA) to assess evidence robustness.

Main Results:

• Levosimendan use was associated with reduced in-hospital mortality (OR 0.64) and ICU length of stay compared to dobutamine.
• Significant reductions in B-type natriuretic peptide (BNP) and serum lactate levels were observed with levosimendan.
• Trial Sequential Analysis indicated insufficient evidence to definitively confirm or exclude effects on mortality.

Conclusions:

• Levosimendan shows potential benefits in improving hemodynamics, tissue perfusion, and biomarkers in SICM patients.
• The drug may reduce in-hospital mortality and ICU length of stay compared to dobutamine.
• Further high-quality studies are necessary to confirm these findings and guide clinical decision-making for inotrope selection in SICM.